SOUTH SAN FRANCISCO, Calif., Oct. 13 /PRNewswire-FirstCall/ -- Exelixis, Inc. announced today that George Scangos, PhD, president and chief executive officer of Exelixis will present at the BIO Investor Forum 2006 Conference at 10:40 a.m. (PT) / 1:40 a.m. (ET) on Wednesday, October 18, 2006.
The presentation will be webcast and may be accessed in the Event Calendar page under Investors on the Exelixis website at www.exelixis.com .
About Exelixis
Exelixis, Inc. is a development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases. The company is leveraging its fully integrated drug discovery platform to fuel the growth of its development pipeline, which is primarily focused on cancer. Currently, Exelixis’ broad product pipeline includes investigational compounds in Phase III (XL119, exclusively out-licensed to Helsinn Healthcare S.A), Phase II, and Phase I clinical development for cancer and renal disease. Exelixis has established strategic corporate alliances with major pharmaceutical and biotechnology companies including GlaxoSmithKline, Bristol-Myers Squibb Company, Genentech, and Sankyo. For more information, please visit the company’s web site at www.exelixis.com .
Exelixis, Inc.
CONTACT: investors, Charles Butler, Director, Corporate Communications ofExelixis, Inc., +1-650-837-7277, or cbutler@exelixis.com, or media, SoleilMaxwell Harrison, Senior Manager, Corporate Communications of Exelixis,Inc., +1-650-837-7012, or sharrison@exelixis.com
Web site: http://www.exelixis.com//
